Multiple Sclerosis, 1 October 2002, vol. 8, no. 6, pp. 534-536(3)
Altintas A.; Alici Y.; Melikoglu M.; Siva A.
 Department of Neurology, Cerrahpasa School of Medicine, 34300 Istanbul, Turkey  Department of Rheumatology, Cerrahpasa School of Medicine, 34300 Istanbul, Turkey
Interferon beta (IFN-b) is the most widely prescribed disease-modifying drug for multiple sclerosis (MS).
Therapy with IFN-b may be associated with a number of adverse reactions.
The development or exacerbation of other autoimmune diseases is a rare but reported side effect of IFN-b therapy.
In this case report, we present clinical and laboratory findings of
two MS patients who developed arthritis during IFN-b1b
treatment, probably of autoimmune origin.